B

대원제약

003220KOSPI

56.0 / 100

Reference Date: 2026-09-08

Financial Score19.0 / 40
News Sentiment17.0 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 2.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Daewon Pharmaceutical operates in pharmaceuticals, cosmetics, and health functional foods, focusing on CMO services, overseas exports, and the development of OTC drugs and health supplements. Key subsidiaries include Daewon Meditech (hearing aid sales), Daewon Pharmaceutical Vietnam (Southeast Asia market expansion), SD Biotech (cosmetics brand 'SNP'), and 'Ogam Shikdak' (a 2022-launched convenience food brand targeting online markets with products like 'Token Broth').

Number of Employees

1,349people

Average Salary

77.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 15.004.0Point
PBR
0.65Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
-1.44Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
44.70Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲7.4% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼50.1% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 3.7% (declining, 3yr)

Detailed News Sentiment

14 totalPositive 7Neutral 6Negative 1Average Sentiment Score 67.9

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 8,000Won52-week high 13,45052-week low 7,240
1-month return3.0Point

1m -1.96% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral공정거래자율준수프로그램운영현황(안내공시)2026-08-28